Table 8.

Indications for allogeneic stem cell transplant in chronic myeloid leukemia.

Chronic phase

Failure to respond to ≥3 TKIs Presence of T315I mutation and/or failure to ponatinib Presence of very high-risk cytogenetic features (e.g., isolated 3q26.2 rearrangement, −7/7q–, i(17q), or with these abnormalities in the context of a complex karyotype) Presence of recurrent severe cytopenias in response to treatment with different TKIs despite dose reduction and cytokine support

Advanced phase

AP patients with non optimal response to frontline TKI BP patients after acquisition of a second CP with TKI (plus optional chemotherapy) AP or BP patients progressing from a previous CP, after reacquistion of a second CP with TKI (plus optional chemotherapy)